HCP

U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Retrieved on: 
Wednesday, December 13, 2023

Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS).

Key Points: 
  • Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS).
  • As orally administered BTKis are already established in oncology, there was a notable level of awareness, familiarity, and anticipation surrounding these developmental assets amongst neurologists.
  • Through Spherix’s quarterly RealTime Dynamix™ market tracker, neurologists and MS specialists have expressed an increasing level of enthusiasm for these investigational therapies over time.
  • With the recent trial outcomes impacting two of the prominent BTKis in development, the optimistic prospects for this class now face uncertainty.

BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake

Retrieved on: 
Thursday, December 7, 2023

There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.

Key Points: 
  • There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.
  • One participating dermatologist highlights, “even though it's not a direct JAK inhibitor, it still is in that same family.
  • Contact rates between BMS sales representatives and healthcare professionals have consistently increased, with the majority now reporting interactions with a Sotyktu representative since launch.
  • An influential factor in reshaping safety perceptions regarding the oral psoriasis treatment involves BMS’ ongoing long-term-extension (LTE) trial, known as POETYK.

HashiCorp Announces Third Quarter of Fiscal Year 2024 Financial Results

Retrieved on: 
Thursday, December 7, 2023

Trailing four quarter average Net Dollar Retention Rate was 119% at the end of the third quarter of fiscal 2024 as compared to 134% at the end of third quarter of fiscal 2023.

Key Points: 
  • Trailing four quarter average Net Dollar Retention Rate was 119% at the end of the third quarter of fiscal 2024 as compared to 134% at the end of third quarter of fiscal 2023.
  • SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced financial results for its third quarter of fiscal 2024, ended October 31, 2023.
  • HashiCorp ended the third quarter of fiscal 2024 with 4,354 customers, up from 4,217 customers at the end of the previous fiscal quarter, and up from 3,648 customers at the end of the third quarter of fiscal 2023.
  • Quarterly subscription revenue from HashiCorp Cloud Platform (HCP) reached $19.9 million in the third quarter of fiscal 2024, up from $18.4 million in the previous fiscal quarter and up from $12.9 million in the third quarter of fiscal 2023.

HashiCorp Awarded 2023 AWS Partner Award

Retrieved on: 
Tuesday, December 5, 2023

SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, is pleased to announce it is the recipient of a 2023 Global AWS Partner Award, recognizing leaders around the globe playing a key role helping customers drive innovation and build solutions on Amazon Web Services (AWS).

Key Points: 
  • SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, is pleased to announce it is the recipient of a 2023 Global AWS Partner Award, recognizing leaders around the globe playing a key role helping customers drive innovation and build solutions on Amazon Web Services (AWS).
  • Announced during the Partner Awards Gala at AWS re:Invent 2023, the Geo and Global AWS Partner Awards recognize a wide range of AWS Partners, whose business models have embraced specialization, innovation, and cooperation over the past year.
  • Geo and Global AWS Partner Awards recognize partners whose business models continue to evolve and thrive on AWS as they work with customers.
  • During re:Invent this year, AWS and HashiCorp announced launch day support for Amazon S3 Express in the HashiCorp Terraform AWS provider and Amazon CodeWhisperer support for Terraform.

IPG Health Agencies Shine in MM+M “Best Places to Work” Program

Retrieved on: 
Tuesday, December 5, 2023

NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IPG Health announced today that three of its agencies have earned coveted spots in MM+M’s annual “Best Places to Work” program which recognizes the world’s best healthcare marketing agencies as scored by their employees and then selected by a panel of judges.

Key Points: 
  • NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IPG Health announced today that three of its agencies have earned coveted spots in MM+M’s annual “Best Places to Work” program which recognizes the world’s best healthcare marketing agencies as scored by their employees and then selected by a panel of judges.
  • Employees were surveyed anonymously and provided candid feedback across categories like well-being and professional growth, internal communication and transparency, flexibility, agency culture, employee benefits, and more.
  • “The beauty of IPG Health continues to be our broad diversity of agency brands and personas across the network.
  • And even though we are all unique and different, we have the same core values emanating from a strong culture at the center,” said Dana Maiman, CEO of IPG Health.

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Retrieved on: 
Thursday, November 30, 2023

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

Key Points: 
  • Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
  • The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
  • Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Industry Partners to Achieve Increased Audience Reach Through Private Marketplace (PMP) Advertising

Retrieved on: 
Thursday, November 16, 2023

This capability enables clients to increase their audience reach and send strategic brand and disease state messages to target audiences in real-time.

Key Points: 
  • This capability enables clients to increase their audience reach and send strategic brand and disease state messages to target audiences in real-time.
  • Endemic advertisements are especially effective because they appear in places that are naturally relevant to the market(s) they target.
  • Through Healiolytics Endemic Programmatic advertising, clients can connect with more than three million HCPs in environments where they are most receptive to health messaging.
  • “Our primary goal is to provide advertisers with innovative solutions for communicating their brand’s value to HCPs in diverse specialties.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on: 
Monday, November 13, 2023

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points: 
  • These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
  • However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
  • This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
  • Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence

Retrieved on: 
Monday, December 18, 2023

Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset.

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset.
  • View the full release here: https://www.businesswire.com/news/home/20231218899992/en/
    Keren Shani, Head of Cell & Gene Therapy at Trinity Life Sciences, speaks with a colleague after an exhilarating strategy session in June 2023.
  • An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room , evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential.
  • Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.

Tandem Diabetes Care Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Retrieved on: 
Tuesday, December 12, 2023

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers (HCPs).

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers (HCPs).
  • Tandem Source is now available for all Tandem pump users and their HCPs in the United States, with international availability expected in 2024.
  • View the full release here: https://www.businesswire.com/news/home/20231212863199/en/
    Tandem Source, a new diabetes management platform for insulin pump users and healthcare providers, now available for all Tandem Diabetes Care customers in the United States.
  • Tandem Source is now available to all Tandem insulin pump users and HCPs based in the United States.